Due to in­creas­ing com­pe­ti­tion, Gala­pa­gos’ CAR-T ex­its au­toim­mune dis­eases

Gala­pa­gos has stopped de­vel­op­ing its CD19 CAR-T can­di­date in au­toim­mune dis­eases, in­clud­ing plans for a tri­al in sys­temic lu­pus ery­the­mato­sus, mark­ing the first no­table ex­it from a space that’s been at­tract­ing new play­ers.

“For strate­gic rea­sons, we de­cid­ed to dis­con­tin­ue the de­vel­op­ment of our CD19 CAR-T pro­gram in au­toim­mune dis­eases,” a Gala­pa­gos spokesper­son told End­points News in an email. “The com­pet­i­tive land­scape has evolved very rapid­ly, with mul­ti­ple com­pa­nies rolling out pro­grams across im­munol­o­gy in­di­ca­tions, of­ten lead­ing with SLE as a first in­di­ca­tion. Hence, the field is very crowd­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER